Atara biotherapeutics joins the rare disease company coalition alongside industry gamechangers

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the company has joined the rare disease company coalition. the coalition represents an alliance of innovative life sciences companies committed to discovering, developing and delivering rare disease treatments for the pa
ATRA Ratings Summary
ATRA Quant Ranking